Telix制药公司报告,在2025年问题2中,收入猛增63%,药物试验达到重大里程碑。 Telix Pharmaceuticals reports a 63% revenue jump and major drug trial milestones in Q2 2025.

Telix制药公司报告说,2025年Q2收入逐年增加63%,达到2.04亿美元,并重申2025年财政年度收入指导为7.7亿至8亿美元。 Telix Pharmaceuticals reported a 63% year-over-year increase in Q2 2025 revenue, reaching $204 million, and reaffirmed its FY 2025 revenue guidance of $770 million to $800 million. 该公司在美国启动了Gozellix公司,收到了一份重要的高管和犯罪控制系统报销代码,并在ProstACT全球第三阶段试验中取得了一个里程碑,为第一部分招募了所有30名病人。 The company launched Gozellix in the U.S., received a crucial HCPCS code for reimbursement, and achieved a milestone in its ProstACT Global Phase 3 trial by recruiting all 30 patients for Part 1. 为了将审判范围扩大至中国、日本和加拿大,还获得了监管批准。 Regulatory approvals were also secured to expand the trial into China, Japan, and Canada.